New patterns of genetic instability in chronic myeloid leukemia: interesting, but not ready for clinical use

por Schiffer, Charles A.
Publicado 2023

Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia

por Ramchandren, Radhakrishnan, Schiffer, Charles A
Publicado 2009

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom?

por Atallah, Ehab, Schiffer, Charles A
Publicado 2020

Challenges in the Clinical Application of the American Society of Clinical Oncology Value Framework: A Medicare Cost-Benefit Analysis in Chronic Lymphocytic Leukemia

por Seymour, Erlene K., Schiffer, Charles A., de Souza, Jonas A.
Publicado 2017

Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity

por Schiffer, Charles A., Cortes, Jorge E., Hochhaus, Andreas, Saglio, Giuseppe, le Coutre, Philipp, Porkka, Kimmo, Mustjoki, Satu, Mohamed, Hesham, Shah, Neil P.
Publicado 2016

Classification of myeloid neoplasms/acute leukemia: Global perspectives and the international consensus classification approach

por Arber, Daniel A., Hasserjian, Robert P., Orazi, Attilio, Mathews, Vikram, Roberts, Andrew W., Schiffer, Charles A., Roug, Anne Stidsholt, Cazzola, Mario, Döhner, Hartmut, Tefferi, Ayalew
Publicado 2022

Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia

por Flynn, Kathryn E., Atallah, Ehab, Lin, Li, Shah, Neil P., Silver, Richard T., Larson, Richard A., Pinilla-Ibarz, Javier, Thompson, James E., Oehler, Vivian G., Radich, Jerald P., Kota, Vamsi, Mauro, Michael J., Schiffer, Charles A., Cortes, Jorge, Weinfurt, Kevin P.
Publicado 2022

Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States

por Padula, William V., Larson, Richard A., Dusetzina, Stacie B., Apperley, Jane F., Hehlmann, Rudiger, Baccarani, Michele, Eigendorff, Ekkehard, Guilhot, Joelle, Guilhot, Francois, Hehlmann, Rudiger, Mahon, Francois-Xavier, Martinelli, Giovanni, Mayer, Jiri, Müller, Martin C., Niederwieser, Dietger, Saussele, Susanne, Schiffer, Charles A., Silver, Richard T., Simonsson, Bengt, Conti, Rena M.
Publicado 2016

Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia

por Atallah, Ehab, Schiffer, Charles A., Weinfurt, Kevin P., Zhang, Mei-Jie, Radich, Jerald P., Oehler, Vivian G., Pinilla-Ibarz, Javier, Deininger, Michael W. N., Lin, Li, Larson, Richard A., Mauro, Michael J., Moore, Joseph O., Ritchie, Ellen K., Shah, Neil P., Silver, Richard T., Wadleigh, Martha, Cortes, Jorge, Thompson, James, Guhl, Jessica, Horowitz, Mary M., Flynn, Kathryn E.
Publicado 2018